KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $110,559 | -77.1% | 78,971 | -50.3% | 0.00% | – |
| Q2 2023 | $481,785 | -64.9% | 159,005 | -27.6% | 0.00% | – |
| Q1 2023 | $1,371,981 | +212.2% | 219,517 | +204.7% | 0.00% | – |
| Q4 2022 | $439,432 | -81.6% | 72,038 | -63.9% | 0.00% | -100.0% |
| Q3 2022 | $2,387,000 | -10.3% | 199,788 | -5.3% | 0.00% | 0.0% |
| Q2 2022 | $2,660,000 | +246.8% | 210,958 | +209.5% | 0.00% | – |
| Q1 2022 | $767,000 | -24.2% | 68,154 | +19.4% | 0.00% | – |
| Q4 2021 | $1,012,000 | -53.5% | 57,067 | -39.7% | 0.00% | – |
| Q3 2021 | $2,177,000 | +515.0% | 94,561 | +521.6% | 0.00% | – |
| Q2 2021 | $354,000 | -36.1% | 15,212 | -14.4% | 0.00% | – |
| Q1 2021 | $554,000 | -76.9% | 17,774 | -70.5% | 0.00% | -100.0% |
| Q4 2020 | $2,398,000 | – | 60,286 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,525,957 | $4,936,340 | 7.88% |
| Foresite Capital Management IV, LLC | 9,671,643 | $13,540,300 | 7.52% |
| Vida Ventures Advisors, LLC | 2,207,772 | $3,090,881 | 4.78% |
| Lynx1 Capital Management LP | 1,997,006 | $2,795,808 | 1.85% |
| Nextech Invest Ltd. | 2,329,480 | $3,261,272 | 0.99% |
| Orbimed Advisors | 8,009,729 | $11,213,621 | 0.24% |
| Novo Holdings A/S | 815,707 | $1,141,990 | 0.08% |
| DAFNA Capital Management LLC | 105,179 | $147,251 | 0.05% |
| GSA CAPITAL PARTNERS LLP | 374,291 | $524 | 0.04% |
| Rock Springs Capital Management LP | 405,811 | $568,135 | 0.02% |